ATRC

AtriCure, Inc.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/04/2026

Business Summary

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

 


VALUATION

P/E

-295.60

Market Cap ($M USD)

$1.42B

Forward P/E

27.01

PEG

0.02

PRICE TO SALES

2.58

PRICE TO BOOK

2.76

EV / EBITDA

57.52

5-Year Average P/E

Free Cash Flow Yield

3.77%

DCF Value

$-3.01

Graham Number

N/A

Price to FCF

26.52

EV to FCF

25.19

Earnings Yield

-0.34%

FCF Yield

3.77%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.10

Next Year EPS Growth Estimate

$1.04

Next Year Revenue Growth Estimate

$97.35B

Return on Equity (ROE)

-0.95%

FREE CASH FLOW

Operating Margin

-0.36%

Debt-to-Equity

0.18

Piotroski F-Score

6

Altman Z-Score

6.05

Return on Invested Capital (ROIC)

-0.34%

Current Ratio

4.29

Quick Ratio

3.18

Net Debt to EBITDA

-3.03

Interest Coverage

-0.27

Gross Profit margin

75.47%

FCF PER SHARE

$1.11

REVENUE PER SHARE

$11.42

Gainseekers Quantitative Analysis

Summary

AtriCure, Inc. presents a perplexing valuation picture. The stock’s market price has been trading significantly below its DCF value, suggesting potential mispricing. However, the negative earnings yield and a sky-high EV to EBITDA ratio raise red flags about its current profitability. Despite this, the forward P/E ratio indicates optimism for future earnings growth, supported by a robust Altman Z-score of 5.64, signaling financial stability. The market seems to be betting on a turnaround, but the path to profitability remains uncertain.

AI Exposure / Tech Reliance

Operating within the Medical Instruments & Supplies industry, AtriCure is well-positioned to leverage AI and modern technology. The healthcare sector is increasingly integrating AI for diagnostics and surgical precision, areas where AtriCure can innovate. This adaptability could enhance their competitive edge and operational efficiency.

The Bull Case

For the discerning GARP investor, AtriCure offers intriguing prospects. The company's forward PEG ratio of 0.02 is a beacon of potential undervaluation, suggesting growth at a reasonable price. A Piotroski F-Score of 5 indicates moderate financial health, while a high gross profit margin of 75.47% underscores strong pricing power. The free cash flow yield, though modest, hints at efficient capital allocation, making it a compelling buy for those betting on future growth.

The Bear Case

Despite some strengths, AtriCure is not without its pitfalls. The negative EPS and operating margin reflect ongoing profitability challenges. High valuation multiples, such as the EV to EBITDA ratio of nearly 69, suggest the stock is priced for perfection without delivering current earnings. Additionally, the stock's proximity to its 52-week low indicates potential technical weakness, raising concerns about investor confidence.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$51.33

Institutional Ownership %

1-Year Beta

1.28

Insider Buying % (6 Mo)

Distance to 52-Week High

53.72%

Distance to 52-Week Low

9.15%

EARNINGS SURPRISE %

103.14%

50-DAY SMA

$28.50

200-DAY SMA

$34.12

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.